

The University of Bradford Institutional Repository

<http://bradscholars.brad.ac.uk>

This work is made available online in accordance with publisher policies. Please refer to the repository record for this item and our Policy Document available from the repository home page for further information.

To see the final version of this work please visit the publisher's website. Access to the published online version may require a subscription.

Link to publisher's version: <http://dx.doi.org/10.1016/j.bmcl.2014.10.025>

Citation: Sola I, Artigas A, Taylor MC et al (2014) Synthesis and antiprotozoal activity of oligomethylene- and p-phenylene-bis(methylene)-linked bis(+)-huprines. *Bioorganic & Medicinal Chemistry Letters*, 24(23): 5435-5438.

Copyright statement: © 2014 Elsevier. Reproduced in accordance with the publisher's self-archiving policy. This manuscript version is made available under the [CC-BY-NC-ND 4.0](https://creativecommons.org/licenses/by-nc-nd/4.0/) license



Synthesis and antiprotozoal activity of oligomethylene- and *p*-phenylene-bis(methylene)-linked bis(+)-huprines

Irene Sola^a, Albert Artigas^a, Martin C. Taylor^b, Stephen Y. Gbedema^c, Belén Pérez^d, Colin W. Wright^c, John M. Kelly^b, Diego Muñoz-Torrero^{a,*}

^a *Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, and Institut de Biomedicina (IBUB), Universitat de Barcelona, Av. Joan XXIII 27-31, 08028-Barcelona, Spain*

^b *Department of Pathogen Molecular Biology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom*

^c *Bradford School of Pharmacy, University of Bradford, West Yorkshire BD7 1 DP, United Kingdom*

^d *Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona, 08193-Bellaterra, Barcelona, Spain*

ABSTRACT

Molecular dimerization of antiprotozoal compounds may be used to overcome drug resistance. Huprines are a class of 4-aminoquinoline derivatives endowed with trypanocidal and antimalarial activities. We have synthesized a series of dimers of (+)-(7R,11R)-huprine Y with linkers of different length and chemical nature and evaluated their activity against cultured bloodstream forms of *Trypanosoma brucei* and *Plasmodium falciparum*, and their cytotoxicity against rat myoblast L6 cells. We also assessed their brain permeability, a requirement in drugs aimed at treating the late stages of infections with these parasites. Most of the new dimers exhibit more potent trypanocidal activity than the parent huprine Y, with IC₉₀ values in the submicromolar range and better selectivity indices (up to 38). They have a predicted ability to cross the blood-brain barrier, but seem to be devoid of significant antimalarial activity. Bis(+)-huprines therefore emerge as interesting brain permeable trypanocidal leads.

* Corresponding author. Tel.: +34-934024533; fax: +34-934035941; e-mail: dmunoztorrero@ub.edu (D. Muñoz-Torrero)

In the last few years, implementation of prevention and control measures has significantly reduced the burden of tropical protozoan diseases such as human African trypanosomiasis (HAT or sleeping sickness) and malaria. However, approximately 70 million people remain at risk of HAT, and in the case of malaria, half of the world's population live in countries where the disease is endemic. Thus, these parasitic infections continue to pose a serious health threat, especially in developing regions.^{1,2}

The causative agents of HAT and malaria are the single-celled parasites *Trypanosoma brucei gambiense* or *T. brucei rhodesiense*, and several species of the genus *Plasmodium*, amongst which, *P. falciparum* is the most common and deadly. The parasites are transmitted through the bite of infected insects, namely *Glossina* flies (tsetse flies) for HAT and *Anopheles* mosquitoes for malaria.

In HAT, following an initial hemolympathic phase, parasites can cross the blood–brain barrier (BBB) and infect the central nervous system (CNS), leading to severe neurological symptoms. Without treatment, death is inevitable when the disease has reached this late stage. In malaria, the parasites multiply initially in the liver, and then in the bloodstream. In severe cases, they can become sequestered within brain capillaries, particularly in children, causing the so-called cerebral malaria, frequently with fatal consequences.

Current options to reduce the burden of HAT and malaria are far from ideal.³⁻⁵ There is no licensed vaccine for either infection, with vector control and public health measures being the main means of prevention. Currently registered drugs are problematic, with toxicity and resistance being major problems. For example, although five drugs have been approved for the treatment of HAT (pentamidine, suramin, melarsoprol, nifurtimox and eflornithine), their activity can be stage and/or species specific, they display a range of toxic side effects, and require strict and complicated parenteral administration regimens.⁶ This type of specialized infrastructure is often unavailable in the poor rural settings where HAT is endemic. Drug resistance continues to emerge and undermine clinical effectiveness. Increased resistance has been observed for the trypanocidal agent melarsoprol. In the case of malaria, chloroquine is no longer widely effective and rising resistance against the current front line drug artemisinin is a potential threat to global health. Overall, there is an acute need to develop novel drugs for HAT and malaria that can circumvent the limitations of existing therapies.

Several approaches have been proposed to speed up the antiprotozoal drug pipeline. These include high-throughput screening of large compound libraries, new strategies to functionally validate novel druggable targets involved in key steps of the parasite life-cycle,⁷⁻¹⁰ or the simultaneous inhibition of two or more key biological targets with combination therapies or multitarget-directed ligands.¹¹⁻¹³ Increasingly, the search for novel antiprotozoal agents also involves the repositioning of existing drugs registered for other applications¹⁴ or the synthesis of new chemical entities endowed with antiprotozoal activity.¹⁵⁻¹⁷

In recent years, new compounds bearing the 4-amino-7-chloroquinoline core of chloroquine, or other aminoquinoline moieties, have been assessed as novel trypanocidal or antimalarial agents, or as dual agents endowed with both activities.¹⁸⁻²¹ The development of single molecules that have potency against different protozoan diseases (such as HAT and malaria) has been regarded as an feasible approach, with potential economic savings.²² We recently reported that the aminoquinoline derivatives huprines, a structural class initially developed as inhibitors of the enzyme acetylcholinesterase, are


moderately effective and selective trypanocidal agents, with some also being active against a chloroquine-resistant strain of *P. falciparum*.^{23,24} In particular, the 4-amino-7-chloroquinoline derivative **1** (huprine Y, Scheme 1) exhibited the lowest IC₅₀ value of the series against *T. brucei* (IC₅₀ = 0.61 μM; IC₉₀ = 2.94 μM), with one of the best selectivity indices over rat myoblast L6 cells (SI = 13) among the entire set of tested huprines.²³

Molecular dimerization of compounds with known antiprotozoal activity constitutes a strategy that can be used to overcome drug resistance.²⁵ This approach has proven successful for dimers of 4-aminoquinolines, in which the two constituting units were connected through linkers of different length or containing different functional groups.²⁶⁻²⁹

Here, we report the synthesis of dimers of huprine Y, in which the two huprine moieties have been connected through oligomethylene linkers of different length, or with a *p*-phenylene-*bis*(methylene) tether. To this end, enantiopure (+)-(7*R*,11*R*)-huprine Y [(7*R*,11*R*)-**1**, Scheme 1], the least active enantiomer in terms of acetylcholinesterase inhibition activity,^{30,32} has been used. The dimeric *bis*(+)-huprines have been tested against cultured bloodstream forms of *T. brucei* and *P. falciparum*, and their cytotoxicity against mammalian cells and brain permeability has been assessed.

The synthesis of hexa-, octa-, deca-, and dodeca-methylene linked *bis*-huprines (+)-**2a–d** and the *p*-phenylene-*bis*(methylene)-linked *bis*-huprine (+)-**2e** was carried out by reaction of 2 equivalents of (+)-(7*R*,11*R*)-huprine Y with 1 equivalent of the corresponding α,ω-dihaloalkane, using KOH as the base in DMSO at room temperature for three days (Scheme 1). After silica gel column chromatography purification, *bis*(+)-huprines (+)-**2a–d** were obtained in moderate yields (21–50% yields, whereas (+)-**2e** was obtained in a lower yield (11%) along with the byproduct resulting from the monoalkylation of (+)-**1** (12% yield).

Bis-huprines (+)-**2a–e** were converted into the corresponding dihydrochlorides for their chemical characterization (specific rotation, melting point, IR, ¹H and ¹³C NMR, HRMS, and elemental analysis) and biological profiling.³³



Scheme 1. Synthesis of *bis*-huprines (+)-**2a–e**.

Bis-huprines (+)-**2a–e** were first tested *in vitro* against cultured bloodstream forms of *T. brucei*. All of the *bis*-huprines exhibited IC₅₀ values in the range 0.50–0.89 μM. Their IC₉₀ values of around 1 μM (0.73–1.09 μM) (Table 1), were significantly lower than the parent huprine Y (IC₉₀ = 2.94 μM).

Given the narrow range of potencies of the different *bis*-huprines, the length of the linker or the presence of a benzene ring within the linker do not seem to have a strong influence on the trypanocidal activity of *bis*(+)-huprines. Thus, the increased trypanocidal potency of *bis*-huprines, relative to huprine Y, might be ascribed to the dimerization strategy, even though the mechanisms responsible for inhibition of trypanosome growth or for the enhanced activity are not known.

Bis-huprines (+)-**2a–e** were also evaluated against the chloroquine-resistant K1 strain of *P. falciparum*. Even though some huprines have been reported to exhibit moderately potent antiparasmodial properties,²³ huprine Y did not exhibit significant activity ($IC_{50} > 10 \mu M$). Huprine Y bears the 4-amino-7-chloroquinoline moiety, thought to be an antimalarial pharmacophore responsible for inhibition of haem dimerization.^{20,34} Since dimerization of other 4-aminoquinoline compounds increased antiparasmodial potency and/or overcame the chloroquine resistance mechanism,^{26–29} we hypothesized that dimerization of huprine Y to *bis*-huprines (+)-**2a–e** might also enhance activity. However, no noticeably increased antiparasmodial potency was observed for the dimeric compounds, which exhibited IC_{50} values $> 5 \mu g/mL$ (i.e. $> 6–7 \mu M$), much higher than that of artemisinin ($IC_{50} = 91 \text{ nM}$) used in this assay as a positive control. The improvement of potency against chloroquine resistant strains of *P. falciparum* of other *bis*(4-aminoquinoline) derivatives relative to the corresponding monomeric compounds has been ascribed mainly to the doubling of the number of protonatable nitrogen atoms in the dimers, which might lead to more efficient trapping in the acidic digestive vacuole of the parasite and prevention of heme polymerization.^{25,29} The failure of *bis*-huprines to show antiparasmodial activity might be indicative of the fact that these compounds cannot hit the biological target of chloroquine and other 4-aminoquinoline derivatives despite their structural similarity. Indeed, we have recently found that the parent huprine Y, unlike chloroquine, shows no inhibition of β -haematin formation, whereas several huprine analogues that possess antiparasmodial activity are effective inhibitors of β -haematin formation (unpublished results).

Table 1
Trypanocidal and cytotoxic activity of *bis*-huprines (+)-**2a–e**^a

Compd	<i>T. brucei</i>	<i>T. brucei</i>	L6 cells	SI ^b
	$IC_{50} \mu M$	$IC_{90} \mu M$	$IC_{50} \mu M$	
(+)- 2a	0.89 ± 0.02	1.09 ± 0.01	1.61 ± 0.07	1.8
(+)- 2b	0.52 ± 0.01	0.74 ± 0.02	4.92 ± 0.15	9.5
(+)- 2c	0.50 ± 0.01	0.73 ± 0.01	7.71 ± 0.70	15.4
(+)- 2d	0.76 ± 0.03	0.99 ± 0.05	28.5 ± 2.9	37.5
(+)- 2e	0.57 ± 0.02	0.75 ± 0.02	16.1 ± 0.3	28.2
huprine Y, 1	0.61 ± 0.03^c	2.94 ± 0.20^c	7.80 ± 0.47^c	12.8

^a *In vitro* activity against bloodstream form of *T. brucei* (pH 7.4) and rat myoblast L6 cells expressed at the concentration that inhibited growth by 50% (IC_{50}) and 90% (IC_{90} , for trypanocidal activity). Data are the mean of triplicate experiments \pm SEM.

^b SI: Selectivity index is the ratio of cytotoxic to trypanocidal IC_{50} values.

^c Taken from ref. 23.

The cytotoxicity of *bis*-huprines was assessed *in vitro* using rat skeletal myoblast L6 cells. These compounds displayed a modest toxicity against the mammalian cells, exhibiting IC_{50}

values in the range 1.6–28.5 μM (Table 1). A clear structure-cytotoxicity trend was found, with cytotoxicity decreasing with increased tether length and with the presence of a benzene ring within the linker. Thus, the dodecamethylene-linked *bis*-huprine (+)-**2d** was found to be 18-, 6-, and 4-fold less cytotoxic than the hexa-, octa-, and deca-methylene counterparts (+)-**2a**, (+)-**2b**, and (+)-**2c**, respectively, whereas the *p*-phenylene-*bis*(methylene)-linked *bis*-huprine (+)-**2e** was 10-fold less cytotoxic than the oligomethylene-linked *bis*-huprine with a similar tether length, (+)-**2a**. Thus, the longest homologue (+)-**2d** and the *p*-phenylene-*bis*(methylene)-linked *bis*-huprine (+)-**2e** displayed the highest selectivity indices for trypanocidal over cytotoxic activity (SI = 37.5 and 28.2, respectively).

Permeability across the BBB is a necessary condition for drug candidates against HAT that are to be effective against late-stage disease, when the CNS is invaded by the parasite. The BBB permeability of *bis*-huprines (+)-**2a–e** was assessed *in vitro* through the widely used parallel artificial membrane permeability assay (PAMPA-BBB), using a lipid extract of porcine brain as the artificial membrane.³⁵ Assay validation was performed by comparing the experimentally observed permeabilities [P_e (exp)] of fourteen marketed drugs with the permeabilities reported in the literature [P_e (lit)], which provided a good linear correlation: P_e (exp) = $1.4974 P_e$ (lit) – 0.8434 ($R^2 = 0.9428$). Taking into account this equation and the limits established by Di *et al.*,³⁵ three ranges of BBB permeation were established: high BBB permeation (CNS+) for those compounds with $P_e (10^{-6} \text{ cm s}^{-1}) > 5.1$; low BBB permeation (CNS–) for those compounds with $P_e (10^{-6} \text{ cm s}^{-1}) < 2.1$; and uncertain BBB permeation (CNS \pm) for those compounds with $5.1 > P_e (10^{-6} \text{ cm s}^{-1}) > 2.1$. All the *bis*-huprines exhibited permeabilities clearly above the threshold established for high BBB permeation (Table 2), even though they seem to be less permeable than monomeric huprine Y. This may arise because they are dibasic compounds and will mostly be in the diprotonated form, whereas monomeric huprine, with only one basic nitrogen atom, will be monoprotinated under the assay conditions.

Table 2
BBB predicted permeabilities of *bis*-(+)-huprines (+)-**2a–d** and parent huprine Y

Compd	$P_e (10^{-6} \text{ cm s}^{-1})^a$	Prediction
(+)- 2a	11.1 ± 0.3	CNS+
(+)- 2b	13.9 ± 1.0	CNS+
(+)- 2c	8.7 ± 1.5	CNS+
(+)- 2d	17.4 ± 0.7	CNS+
(+)- 2e	8.3 ± 0.6	CNS+
huprine Y, 1	23.8 ± 2.7^b	CNS+

^a Values are expressed as mean \pm SD of three independent experiments.

^b Taken from ref. 32.

In summary, we report the synthesis of a series of dimeric *bis*(4-aminoquinoline) derivatives, which are composed of two units of (+)-(*7R,11R*)-huprine Y connected through oligomethylene linkers of different length or a *p*-phenylene-*bis*(methylene) linker. We also describe the assessment of the different *bis*(+)-huprines on the growth of bloodstream forms of *T. brucei* and *P. falciparum*, and of rat skeletal myoblast L6 cells, as well as their BBB permeability. All of the *bis*(+)-huprines exhibited potent trypanocidal activity, with IC_{50} and IC_{90} values in the submicromolar range. However, they did not exhibit significant antiparasmodial activity. As trypanocidal agents, *bis*(+)-huprines are more potent than monomeric huprine Y and

some of them, particularly the dodecamethylene- and *p*-phenylene-*bis*(methylene)-linked dimers (+)-**2d** and (+)-**2e**, are less cytotoxic and, hence, more selective for *T. brucei* over rat L6 cells growth inhibition than huprine Y. All the *bis*(+)-huprines have been predicted to have the ability to cross the BBB, thereby being potentially useful for the treatment of late-stage HAT. Overall, *bis*(+)-huprines (+)-**2d** and (+)-**2e** emerge as interesting lead compounds for further trypanocidal drug discovery endeavours.

Acknowledgments

This work was supported by Ministerio de Ciencia e Innovación (MICINN) (CTQ2011-22433) and Generalitat de Catalunya (GC) (2014SGR52). JMK acknowledges funding support from the Wellcome Trust (Grant number WT084175). A fellowship from GC to I.S. is gratefully acknowledged. SYG is grateful to the Commonwealth Scholarship Secretariat, UK, and to the Government of Ghana for financial support.

Supplementary data

Supplementary data (synthetic procedures and chemical characterization of *bis*(+)-huprines and biological methods) associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/...>

References and notes

1. Simarro, P. P.; Cecchi, G.; Franco, J. R.; Paone, M.; Diarra, A.; Ruiz-Postigo, J. A.; Fevre, E. M.; Mattioli, R. C.; Jannin, J. G. *PLoS Negl. Trop. Dis.* **2012**, *6*, e1859.
2. World Health Organization. World Malaria Report 2013.
3. Espuelas, S.; Plano, D.; Nguewa, P.; Font, M.; Palop, J. A.; Irache, J. M.; Sanmartín, C. *Curr. Med. Chem.* **2012**, *19*, 4259.
4. Hu, L.; Patel, A.; Bondada, L.; Yang, S.; Wang, M. Z.; Munde, M.; Wilson, W. D.; Wenzler, T.; Brun, R.; Boykin, D. W. *Bioorg. Med. Chem.* **2013**, *21*, 6732.
5. Faist, J.; Seebacher, W.; Kaiser, M.; Brun, R.; Saf, R.; Weis, R. *Bioorg. Med. Chem.* **2013**, *21*, 4988.
6. Phillips, M. A. *Mol. Microbiol.* **2012**, *86*, 10.
7. Fairlamb, A. H. *Nature* **2012**, *482*, 167.
8. Alsford, S.; Eckert, S.; Baker, N.; Glover, L.; Sanchez-Flores, A.; Leung, K. F.; Turner, D. J.; Field, M. C.; Berriman, M.; Horn, D. *Nature* **2012**, *482*, 232.
9. Gilbert, I. H. *J. Med. Chem.* **2013**, *56*, 7719.
10. Spinks, D.; Shanks, E. J.; Cleghorn, L. A. T.; McElroy, S.; Jones, D.; James, D.; Fairlamb, A. H.; Frearson, J. A.; Wyatt, P. G.; Gilbert, I. H. *ChemMedChem* **2009**, *4*, 2060.
11. Belluti, F.; Uliassi, E.; Veronesi, G.; Bergamini, C.; Kaiser, M.; Brun, R.; Viola, A.; Fato, R.; Michels, P. A. M.; Krauth-Siegel, R. L.; Cavalli, A.; Bolognesi, M. L. *ChemMedChem* **2014**, *9*, 371.
12. Njogu, P. M.; Chibale, K. *Curr. Med. Chem.* **2013**, *20*, 1715.
13. Prati, F.; Uliassi, E.; Bolognesi, M. L. *MedChemComm* **2014**, *5*, 853.
14. Njoroge, M.; Njuguna, N. M.; Mutai, P.; Ongarora, D. S. B.; Smith, P. W.; Chibale, K. *Chem. Rev.* **2014**, in press, DOI: 10.1021/cr500098f.
15. Persch, E.; Bryson, S.; Todoroff, N. K.; Eberle, C.; Thelemann, J.; Dirdjaja, N.; Kaiser, M.; Weber, M.; Derbani, H.; Brun, R.; Schneider, G.; Pai, E. F.; Krauth-Siegel, R. L.; Diederich, F. *ChemMedChem* **2014**, *9*, 1880.
16. Stich, A.; Ponte-Sucré, A.; Holzgrabe, U. *Lancet Infect. Dis.* **2013**, *13*, 733.
17. Ferrins, L.; Rahmani, R.; Baell, J. B. *Future Med. Chem.* **2013**, *5*, 1801.
18. Upadhyaya, R. S.; Dixit, S. S.; Földesi, A.; Chattopadhyaya, J. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 2750.
19. Rashad, A. A.; Jones, A. J.; Avery, V. M.; Baell, J.; Keller, P. A. *ACS Med. Chem. Lett.* **2014**, *5*, 496.
20. Musonda, C. C.; Yardley, V.; Carvalho de Souza, R. C.; Ncokazi, K.; Egan, T. J.; Chibale, K. *Org. Biomol. Chem.* **2008**, *6*, 4446.
21. Musonda, C. C.; Gut, J.; Rosenthal, P. J.; Yardley, V.; Carvalho de Souza, R. C.; Chibale, K. *Bioorg. Med. Chem.* **2006**, *14*, 5605.
22. Chibale, K. *Pure Appl. Chem.* **2005**, *77*, 1957.
23. Defaux, J.; Sala, M.; Formosa, X.; Galdeano, C.; Taylor, M. C.; Alobaid, W. A. A.; Kelly, J. M.; Wright, C. W.; Camps, P.; Muñoz-Torrero, D. *Bioorg. Med. Chem.* **2011**, *19*, 1702.
24. Oluwafemi, A. J.; Okanla, E. O.; Camps, P.; Muñoz-Torrero, D.; Mackey, Z. B.; Chiang, P. K.; Seville, S.; Wright, C. W. *Nat. Prod. Commun.* **2009**, *4*, 193.
25. Kaur, K.; Jain, M.; Reddy, R. P.; Jain, R. *Eur. J. Med. Chem.* **2010**, *45*, 3245.
26. Girault, S.; Grellier, P.; Berecibar, A.; Maes, L.; Lemièrre, P.; Muray, E.; Davioud-Charvet, E.; Sergheraert, C. *J. Med. Chem.* **2001**, *44*, 1658.
27. Ayad, F.; Tilley, L.; Deady, L. W. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 2075.
28. Cowman, A. F.; Deady, L. W.; Deharo, E.; Desneves, J.; Tilley, L. *Aust. J. Chem.* **1997**, *50*, 1091.
29. Girault, S.; Grellier, P.; Berecibar, A.; Maes, L.; Mouray, E.; Lemièrre, P.; Debreu, M.-A.; Davioud-Charvet, E.; Sergheraert, C. *J. Med. Chem.* **2000**, *43*, 2646.
30. Camps, P.; Contreras, J.; Font-Bardia, M.; Morral, J.; Muñoz-Torrero, D.; Solans, X. *Tetrahedron: Asymmetry* **1998**, *9*, 835.
31. Camps, P.; El Achab, R.; Morral, J.; Muñoz-Torrero, D.; Badia, A.; Baños, J. E.; Vivas, N. M.; Barril, X.; Orozco, M.; Luque, F. J. *J. Med. Chem.* **2000**, *43*, 4657.
32. Viayna, E.; Sola, I.; Bartolini, M.; De Simone, A.; Tapia-Rojas, C.; Serrano, F. G.; Sabaté, R.; Juárez-Jiménez, J.; Pérez, B.; Luque, F. J.; Andrisano, V.; Clos, M. V.; Inestrosa, N. C.; Muñoz-Torrero, D. *J. Med. Chem.* **2014**, *57*, 2549.
33. The synthetic procedure for the preparation of *bis*(+)-huprines is exemplified by the synthesis and chemical characterization of (+)-**2d**: (+)-*N,N'*-*bis*[(7*R*,11*R*)-3-chloro-6,7,10,11-tetrahydro-9-methyl-7,11-methanocicloocta[*b*]quinolin-12-yl]-1,12-dodecane-diamine. A suspension of (+)-huprine Y, (+)-**1** (500 mg, 1.76 mmol, 2 equiv) and finely powdered KOH (85% purity, 347 mg, 5.26 mmol, 6 equiv), and 4 Å molecular sieves (approx. 1 g) in anhydrous DMSO (10 mL) was stirred, heating every 10 min approximately with a heat gun for 1 h and at rt one additional hour, and then treated with a solution of 1,12-dibromododecane (289 mg, 0.88 mmol, 1 equiv) in DMSO (4 mL) dropwise for 30 min. The reaction mixture was stirred at room temperature for 3 days, diluted with 5N NaOH (100 mL) and H₂O (50 mL), and extracted with EtOAc (2×200 mL). The combined organic extracts were washed with H₂O (2×50 mL), dried over anhydrous Na₂SO₄, and evaporated under reduced pressure to give a yellow oil (614 mg), which was purified through column chromatography (40–60 µm silica gel, CH₂Cl₂/50% aq. NH₄OH 100:0.2), to afford *bis*-huprine (+)-**2d** (323 mg, 50% yield); *R*_f 0.75 (CH₂Cl₂/MeOH/50% aq. NH₄OH 9:1:0.05). A solution of (+)-**2d** (0.23 mg, 0.30 mmol) in CH₂Cl₂ (4 mL) was filtered through a 22 µm PTFE filter, treated with methanolic HCl (0.43 N, 4.2 mL) and evaporated under reduced pressure. The resulting solid was washed with pentane (3×2 mL) to give, after drying at 65 °C/2 Torr for 48 h, (+)-**2d**·2HCl (199 mg) as a yellowish solid; [α]_D²⁰ = + 239 (MeOH, *c* = 0.6); mp 179–181 °C; IR (KBr) ν 3500–2500 (max at 3208, 3050, 3002, 2924, 2849, 2733, N-H, N⁺-H and C-H st), 1631, 1582, 1567, 1514 (ar-C-C and ar-C-N st) cm⁻¹; ¹H NMR (400 MHz, CD₃OD) δ 1.22–1.48 [complex signal, 16H, 3(10)-H₂, 4(9)-H₂, 5(8)-H₂, 6(7)-H₂], 1.58 [s, 6H, 9'(9'')-CH₃], 1.80–1.94 [complex signal, 6H, 2(11)-H₂, 13'(13'')-H_{syn}], 1.93 [d, *J* = 17.6 Hz, 2H, 10'(10'')-H_{endo}], 2.08 [br d, *J* = 12.4 Hz, 2H, 13'(13'')-H_{anti}], 2.55 [dd, *J* = 17.6 Hz, *J'* = 4.4 Hz, 2H, 10'(10'')-H_{exo}], 2.77 [m, 2H, 7'(7'')-H], 2.87 [d, *J* = 17.6 Hz, 2H, 6'(6'')-H_{endo}], 3.21 [dd, *J* = 17.6 Hz, *J'* = 5.2 Hz, 2H, 6'(6'')-H_{exo}], 3.45 [m, 2H, 11'(11'')-H], 3.98 [t, *J* = 6.8 Hz, 4H, 1(12)-H₂], 4.85 (s, NH, NH⁺), 5.58 [br d, *J* = 4.0 Hz, 2H, 8'(8'')-H], 7.54 [dd, *J* = 9.2 Hz, *J'* = 1.2 Hz, 2H, 2'(2'')-H], 7.77 [br s, 2H, 4'(4'')-H], 8.39 [d, *J* = 9.2 Hz, 2H, 1'(1'')-H]; ¹³C NMR (100.6 MHz, CD₃OD) δ 23.5 [CH₃, 9'(9'')-CH₃], 27.3 [CH, C11a'(11'')], 27.83 [CH₂, C3(10)], 27.85 [CH, C7'(7'')], 29.3 [CH₂, C13'(13'')], 30.3 (CH₂) and 30.6 (2CH₂) [C4(9), C5(8), C6(7)], 31.2 [CH₂, C2(11)], 36.0 [CH₂, C10'(10'')], 36.1 [CH₂, C6'(6'')], 49.7 [CH₂, C1(12)], 115.6 (C) and 117.6 (C) [C11a'(11''), C12a'(12'')], 119.1 [CH, C4'(4'')], 125.2 [CH, C8'(8'')], 126.6 [CH, C2'(2'')], 129.5 [CH, C1'(1'')], 134.5 [C, C9'(9'')], 140.2 [C, C3'(3'')], 141.0 [C, C4a'(4a'')], 151.2 [C, C5a'(5a'')], 156.9 [C, C12'(12'')]. HRMS (ESI) calcd for (C₄₆H₅₆³⁵Cl₂N₄ + H⁺): 735.3955, found 735.3960. Anal. calcd

for (C₄₆H₅₆Cl₂N₄·2HCl·1.25H₂O): C 66.46%, H 7.34%, N 6.74%;
found: C 66.63%, H 7.66%, N 6.23%.

34. Egan, T. J. *Drug Des. Rev.* **2004**, *1*, 93.
35. Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. *Eur. J. Med. Chem.* **2003**, *38*, 223.